PepGen (PEPG) Prices $125M Offering at $5.00 per Share

PepGen priced 25M shares at $5.00 each, raising $125M before costs. Underwriters have a 30-day option for 3.75M more shares. The company did not provide prior-period comparisons.

Original reporting
Published Nov 12, 2026, 3:22 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 3:28 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
PepGen (PEPG) Prices $125M Offering at $5.00 per Share — source image
Decision brief

The 30-second read

$PEPGBearishMed
01

Why it matters

The infusion of $125M strengthens the balance sheet but adds dilution, likely pressuring the stock in the short term.

02

Market read

First report of a sizable equity raise for a micro‑cap biotech, providing new trading information.

03

What to watch

Potential strategic partnership or pipeline milestones that may follow the capital infusion.

Relevance 8/10Novelty 8/10Timing: today

Background

PepGen announced a primary public offering of 25M shares at $5.00 each, with a 30‑day over‑allotment option for 3.75M additional shares.

Company-level read

Ticker impact

$PEPGBearishHigh confidence
Context

PepGen priced a $125M offering at $5.00 per share, raising $125M before costs.

Expected impact

likely pressure as the market prices in dilution from the $125M raise

Evidence & confidence

New financing of this size is material for a micro‑cap biotech and typically triggers short‑term sell pressure.

Market effects

Biotech financing activity may signal investor appetite for clinical‑stage companies.

US biotech sector could see modest ripple as peers assess dilution risk.

Limited to biotech investors; no broad market effect.

Counterpoint

The raise could fund pivotal trials that unlock value, offsetting dilution concerns.

Key entities

  • PepGen Inc.

    Clinical‑stage biotechnology company raising capital.

Related articles

MedAI 8/10

PepGen’s stock skyrockets on record-breaking DM1 trial data

PepGen's stock surged 132% after its Phase II trial for PGN-EDODM1 in myotonic dystrophy type 1 (DM1) met endpoints, showing high genetic modulation and functional improvements. The stock later closed at $4.61, up 92.9% from the previous close. The trial demonstrated significant splicing correction and tolerability, with data supporting continued development. PepGen expects more data in 2027.

$PEPGHighAI 8/10

PepGen Stock Doubles in One Session - Here's Why

PepGen Inc. (PEPG) stock surged 111.30% to $5.05 on Tuesday after reporting positive Phase 2 trial results for its myotonic dystrophy type 1 treatment, showing significant splicing correction and functional improvements in patients. The company reported a 46.5% average muscle splicing correction at 10 mg/kg dose, with notable gains in mobility and hand grip strength. PepGen expects to release further data in 2027.